🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

💡How can we harness a patient’s own immune system to fight cancer? Amgen 🧪🔬🧬’s Judd Englert, MD,PhD & I-Fen Chang share the cutting-edge innovation behind our Bispecific T-cell Engager (BiTE®) technology ⬇️

🔍Meet #DLL3 – a protein that’s highly prevalent in small cell lung cancer. At Amgen 🧪🔬🧬, we’re targeting DLL3 to provide new options for patients battling this aggressive disease.

Hope begins with care that sees the individual. This #WorldCancerDay 🌍 Amgen 🧪🔬🧬’s patient advocacy allies share how hope & collaboration inspire action and healing. #UnitedByUnique

Each cancer journey is unique, but we’re united in the fight for a brighter future. This #WorldCancerDay, we stand with Union for International #CancerControl to advocate for the unique experiences and needs of those affected by cancer. #UnitedbyUnique 🔗amgen.com/stories/2025/0…

At Amgen 🧪🔬🧬, we’re united in the fight against cancer. 💙 ⬇️Our team members share how progress for patients makes them feel. #UnitedByUnique #WorldCancerDay 🌍

🚨Lung cancer screening rates are critically low in the U.S. – only about 16% of people who are eligible get screened. This #NationalCancerPreventionMonth, let’s raise awareness & encourage action. Early detection matters. 🔗Learn more: cancer.org/health-care-pr…

🔬FGFR2b protein overexpression is an emerging biomarker of interest in #GastricCancer. It fuels tumor growth and may be correlated with shorter survival, making it a potential prognostic marker. Dive deeper into the science behind FGFR2b:

How can we bring hope to those facing lung cancer around the world? 🌍 At Amgen 🧪🔬🧬, we’re building on our progress in non-small cell lung cancer (#NSCLC) to drive advances for patients worldwide.

🧬The future of oncology is here. Amgen 🧪🔬🧬’s BiTE® technology is revolutionizing care, using the power of the body’s immune system to fight cancers with precision. ⬇️Hear how this innovative approach offers hope in the fight against cancer.

#ColorectalCancer is personal for Amgen 🧪🔬🧬’s Brent Serson. Losing both his grandfather & father to the disease fuels his passion for advancing new treatment options. This #CRCAwarenessMonth, we honor all those impacted & remain dedicated to advancing care. 💙🎗️

🩺What’s next in #MultipleMyeloma care? International Myeloma Foundation’s Joseph Mikhael shares how advances in treatment & access can help patients. 🔗wwwext.amgen.com/stories/2025/0… #MyelomaActionMonth

Throughout #MyelomaActionMonth, we are working alongside International Myeloma Foundation to strengthen the myeloma community and raise awareness for those affected by the disease. #AmgenSponsored

We're celebrating Myeloma Action Month by sharing our myeloma milestones! Our stories of resilience inspire others & strengthen the community. Download the template at myelomaactionmonth.org & share yours with #MyelomaMilestone. We thank Amgen 🧪🔬🧬 for helping us raise MM awareness!

#MultipleMyeloma is the 3rd most common blood cancer worldwide. This #MyelomaActionMonth, we stand with the global multiple myeloma community to raise awareness & drive progress toward better care. Learn more at myeloma.org/?utm_source=x&… 💜

#SCLC remains one of oncology's biggest challenges – but there's hope on the horizon. 🎯 DLL3-targeted technologies are unlocking innovative therapeutic approaches. 🔗 Learn more at dll3possibilities.com/?utm_source=x&…

🧬Biomarker innovation has revolutionized #ColorectalCancer (CRC) care, bringing new hope to this global challenge. ⬇️ Fight Colorectal Cancer’s AnjeeDavis shares how testing for biomarkers — like the KRAS G12C mutation — can help personalize care. 🔗Learn more: findkrasg12c.com/mcrc?utm_sourc…

🚨In 2025, approximately 28% of newly diagnosed #AcuteLymphoblasticLeukemia patients will be ages 15-39. Navigating blood cancer as an adolescent or young adult (AYA) comes with unique challenges. Find support with Stupid Cancer: stupidcancer.org/resources/?utm… #AYACancerAwarenessWeek

Founded 45 years ago this week, Amgen 🧪🔬🧬 continues to pioneer groundbreaking oncology research with a 🌏global impact. Discover how we take on cancer’s toughest challenges ⬇️

#SCLC is an aggressive cancer, and patients urgently need more options. 🔗 Learn more: amgen.ly/4jy1IoG

🚀A new era of #GastricCancer care is on the horizon. Amgen 🧪🔬🧬’s #FGFR2b research is driving 🎯targeted investigative approaches. 🔗Learn more at fgfr2b.com/?utm_source=x&…